2017
DOI: 10.1002/ana.25083
|View full text |Cite
|
Sign up to set email alerts
|

Molecular‐based diagnosis of multiple sclerosis and its progressive stage

Abstract: Objective Biomarkers aid diagnosis, allow inexpensive screening of therapies and guide selection of patient-specific therapeutic regimens in most internal medicine disciplines. In contrast, neurology lacks validated measurements of the physiological status, or dysfunction(s) of cells of the central nervous system (CNS). Accordingly, patients with chronic neurological diseases are often treated with a single disease-modifying therapy without understanding patient-specific drivers of disability. Therefore, using… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

3
55
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 43 publications
(59 citation statements)
references
References 33 publications
3
55
1
Order By: Relevance
“…The objective of CV is to extract true global variation, while ignoring variation unique to the dataset alone. An independent validation cohort as utilized by Barbour et al would of course be superior to this approach and of great value to confirm our findings 7 . To check for overfitting in the models used in the variable selection, the models were rebuilt using all patients and the R 2 and Q 2 were extracted, where R 2 describes how well the data explain the groups and Q 2 is analogous to R 2 except for being based on CV.…”
Section: Discussionsupporting
confidence: 68%
See 2 more Smart Citations
“…The objective of CV is to extract true global variation, while ignoring variation unique to the dataset alone. An independent validation cohort as utilized by Barbour et al would of course be superior to this approach and of great value to confirm our findings 7 . To check for overfitting in the models used in the variable selection, the models were rebuilt using all patients and the R 2 and Q 2 were extracted, where R 2 describes how well the data explain the groups and Q 2 is analogous to R 2 except for being based on CV.…”
Section: Discussionsupporting
confidence: 68%
“…Additionally, there were only four patients who transitioned from RRMS to SPMS during the follow-up period, limiting our findings for early detection. The fact that Barbour et al attained a different set of protein markers (then evaluated as protein ratios) than extracted herein indicates that there are more proteins of interest for use in MS diagnostics 7 . Finally, as half of the RRMS patients (n=15) and one of the SPMS patients were on ongoing treatments, these treatments could potentially affect the top candidate variables.…”
Section: Discussionmentioning
confidence: 90%
See 1 more Smart Citation
“…To overcome this problem, the question regarding potential biomarkers for MS diagnosis and clinical subtypes has recently been approached with an innovative technology. By using an unbiased simultaneous screening for the concentration of 1.128 proteins together with new machine learning and bioinformatics technology, CSF protein profiles were established in a large sample of patients with RRMS, SPMS, and PPMS and the findings were compared with those seen in patients with other inflammatory and non-inflammatory CNS diseases (35). Using these new tools profiles were detected, which allowed to differentiate between MS and other inflammatory or non-inflammatory CNS diseases and to clearly separate RRMS from progressive forms of the disease.…”
Section: Immunology and Biomarkersmentioning
confidence: 99%
“…While the metabolite changes identified correlated with EDSS and MRI measures of neurodegeneration, their diagnostic accuracy is not known 17,18 . In CSF, a panel of 250 proteins has been identified which is able to distinguish between RRMS and progressive (SPMS and PPMS combined) MS with an accuracy of 89.4% in a validation cohort 19 . While such a test could be useful, monitoring of the transition from RRMS to SPMS in a clinical setting may be challenging due to the high cost of measuring large panels of proteins coupled with the invasive nature of CSF sampling.…”
mentioning
confidence: 99%